Drug Type Antibody drug conjugate (ADC)  | 
Synonyms MP-HER3-ADC  | 
Target  | 
Action antagonists, inhibitors  | 
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists), Tubulin inhibitors  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
Molecular FormulaC39H65N5O8  | 
InChIKeyMFRNYXJJRJQHNW-DEMKXPNLSA-N  | 
CAS Registry745017-94-1  | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | Italy   | 20 Apr 2023 | 






